247 related articles for article (PubMed ID: 25519790)
21. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
23. Predictors of antiretroviral treatment-associated tuberculosis in Ethiopia: a nested case-control study.
Mesfin N; Deribew A; Yami A; Solomon T; Van Geertruyden JP; Colebunders R
Int J STD AIDS; 2012 Feb; 23(2):94-8. PubMed ID: 22422682
[TBL] [Abstract][Full Text] [Related]
24. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
PLoS One; 2012; 7(3):e34156. PubMed ID: 22479548
[TBL] [Abstract][Full Text] [Related]
25. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
26. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.
Lawn SD; Myer L; Edwards D; Bekker LG; Wood R
AIDS; 2009 Aug; 23(13):1717-25. PubMed ID: 19461502
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
[TBL] [Abstract][Full Text] [Related]
29. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.
Nakanjako D; Kiragga AN; Musick BS; Yiannoutsos CT; Wools-Kaloustian K; Diero L; Oyaro P; Lugina E; Ssali JC; Kambugu A; Easterbrook P
AIDS; 2016 Jul; 30(12):1913-22. PubMed ID: 26959510
[TBL] [Abstract][Full Text] [Related]
30. Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model.
Gatechompol S; Sophonphan J; Ubolyam S; Avihingsanon A; van Leth F; Cobelens F; Kerr SJ
BMC Infect Dis; 2022 Apr; 22(1):346. PubMed ID: 35387594
[TBL] [Abstract][Full Text] [Related]
31. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy.
Manosuthi W; Kiertiburanakul S; Phoorisri T; Sungkanuparph S
J Infect; 2006 Dec; 53(6):357-63. PubMed ID: 16487593
[TBL] [Abstract][Full Text] [Related]
32. [Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis].
Zimina VN; Kravchenko AV
Ter Arkh; 2015; 87(11):37-41. PubMed ID: 26821414
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Kiwuwa-Muyingo S; Kikaire B; Mambule I; Musana H; Musoro G; Gilks CF; Levin JB; Walker AS
AIDS; 2014 Nov; 28(17):2579-88. PubMed ID: 25574960
[TBL] [Abstract][Full Text] [Related]
34. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
[TBL] [Abstract][Full Text] [Related]
35. Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda.
Kirenga BJ; Worodria W; Massinga-Loembe M; Nalwoga T; Manabe YC; Kestens L; Colebunders R; Mayanja-Kizza H
Int J Tuberc Lung Dis; 2013 Mar; 17(3):336-41. PubMed ID: 23407223
[TBL] [Abstract][Full Text] [Related]
36. Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013.
Norrby M; Wannheden C; Ekström AM; Berggren I; Lindquist L
Infect Dis (Lond); 2018; 50(11-12):807-816. PubMed ID: 30362392
[TBL] [Abstract][Full Text] [Related]
37. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.
Lawn SD; Myer L; Bekker LG; Wood R
AIDS; 2006 Aug; 20(12):1605-12. PubMed ID: 16868441
[TBL] [Abstract][Full Text] [Related]
38. Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004-2012.
Pathmanathan I; Dokubo EK; Shiraishi RW; Agolory SG; Auld AF; Onotu D; Odafe S; Dalhatu I; Abiri O; Debem HC; Bashorun A; Ellerbrock T
PLoS One; 2017; 12(3):e0173309. PubMed ID: 28282390
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.
Eholié SP; Badje A; Kouame GM; N'takpe JB; Moh R; Danel C; Anglaret X
AIDS Res Ther; 2016; 13():27. PubMed ID: 27462361
[TBL] [Abstract][Full Text] [Related]
40. Factors Associated with Immunological Discordance in HIV-Infected Patients Receiving Antiretroviral Therapy with Complete Viral Suppression in a Resource-Limited Setting.
Mingbunjerdsuk P; Asdamongkol N; Sungkanuparph S
Jpn J Infect Dis; 2015; 68(4):301-4. PubMed ID: 25720640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
